Iterum Therapeutics Bermuda Limited., is a Bermuda exempted company limited by shares incorporated on November 6, 2019. They are a direct wholly owned finance subsidiary of the Parent; (Iterum Therapeutics plc, a public limited company formed under the laws of Ireland. Registered office located at Block 2 Floor 3, Harcourt Centre, Harcourt Street, Dublin 2, Ireland) It is intended that the Issuer will be managed and controlled in Ireland on an on-going basis. Issuer’s Registered office is located at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda.

Exchangeable Notes in an aggregate principal amount of $51,588,000 were issued under an indenture, dated as of January 21, 2020, by and among Iterum Therapeutics Bermuda Limited (the “Issuer”), Iterum Therapeutics plc (the “Parent”), Iterum Therapeutics International Limited, Iterum Therapeutics US Limited and Iterum Therapeutics US Holding Limited (the Parent, Iterum Therapeutics International Limited, Iterum Therapeutics US Limited and Iterum Therapeutics US Holding Limited collectively, the “Guarantors”) and U.S. Bank National Association, as trustee, (the “Exchangeable Notes Indenture”) in a private placement (the “Private Placement”) pursuant to a securities purchase agreement by and among the Issuer, the Guarantors and the investors thereto (the “Purchase Agreement”), and additional Exchangeable Notes in an aggregate principal amount of $220,000 were issued to the holders of Parent ordinary shares as of the record date, August 5, 2020, pursuant to a rights offering (the “Rights Offering”), which closed on September 8, 2020.

Iterum Therapeutics Bermuda Limited., US$$51,588,000 - 6.500% Exchangeable Senior Subordinated Notes due January 31, 2025.,